roch bristol report compel data set
like market loss merck
page full analyst note may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim may
price data may
rate updat may
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
merck combin wide line-up high-margin drug
pipelin new drug ensur strong return invest
capit long term merck worst
patent cliff remov heighten gener
competit compani experienc past year
sever year moder research develop
product merck drug develop strategi yield
merck new product mitig gener competit
offset recent major patent loss particular keytruda
cancer repres key blockbust multi-billion-dollar
potenti hold first-mov advantag one largest
cancer indic non-smal cell lung cancer also expect
new cancer drug combin propel merck overal
drug sale howev expect intens competit cancer
market sever competit drug like report import
clinic data headwind includ
gener competit notabl cardiovascular drug zetia
vytorin like creat drag overal growth
migrain safeti question end
sever year mix result merck product
improv compani shift toward area unmet
medic need owe side effect lack compel efficaci
merck experienc major setback cardiovascular diseas
drug anacetrapib tredapt rolofyllin tra along
develop osteoporosi drug odanacatib despit
setback merck solid success includ success
launch drug keytruda oncolog follow
success merck shift focu toward area unmet medic
need specialty-car area keytruda lead new
direct expect keytruda leadership non-smal cell lung
cancer key driver growth compani next
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note gaap report dilut ep differ model due
merck make pharmaceut product treat sever condit
number therapeut area includ cardiovascular diseas asthma
cancer infect within cancer firm immuno-oncolog platform
grow major contributor overal sale compani also
substanti vaccin busi treatment prevent hepat
pediatr diseas well hpv shingl addit merck sell
anim health-rel drug geograph perspect close
firm sale gener unit state
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
roch bristol report compel data
set like market loss merck may
roch bristol-my squibb releas data
annual american societi clinic oncolog meet
weigh merck lead spot import non-
small-cel lung cancer market base data
increas roch fair valu estim
decreas merck fair valu estim
maintain bristol fair valu
estim see immuno-oncolog platform
firm strong support wide moat rate
roch releas strong tiragolumab phase data first-lin
nsclc combin tecentriq reduc risk
progress death patient high level
express versu tecentriq alon also
tiragolumab didnt appear add safeti concern
data need confirm phase studi data like
monotherapi benefit tecentriq
unusu low set potenti stronger rel
perform tiragolumab still believ data
strong enough support increas assum market
share roch nonsquam nsclc
larg expens merck share fall
merck develop anti-tigit drug
similar mechan action tiragolumab like
data chemotherapi still hold excel data set
high bar new therapi
bristol also report data attack merck leadership
nsclc data checkmat doesnt look
significantli chang
surviv fairli similar benefit seen
merck keytruda plu chemotherapi howev
low patient area keytruda effect
abl will take chemotherapi long term bristol
combo still look well posit gain close
overal nsclc market
slightli lower merck fair valu estim
base strong competit data roch
tiragolumab data need confirm phase
studi data like believ strong result
increas roch market share nonsquam nsclc
larg expens merck
share fall howev merck
develop anti-tigit drug similar mechan action
tiragolumab like least year behind roch
combin data
new therapi
despit challeng keytruda merck still look well
posit keytruda cancer drug lynparza well
hpv vaccin gardasil expect keytruda gain
lion share late stage non-smal cell lung cancer
nsclc market well close adjuv
nsclc market continu expect steadi long-term
growth entir firm partli driven solid outlook
cancer drug keytruda lesser extent strong
outlook hpv vaccin gardasil larg intern
market keytruda key merck valuat
expect leader immuno-oncolog market
expect drug reach peak sale billion
larg base strong efficaci sever cancer type
includ lung head neck melanoma sever
cancer indic look entir compani
next five year expect merck post
annual top-lin growth new drug offset drug lost
gener competit potenti game changer
growth rate includ compani pipelin immuno-oncolog
drug move quickli clinic develop
merck still face gener competit older drug
remicad immunolog zetia cardiovascular vytorin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
key factor affect scenario analysi includ
degre success brand drug pipelin along
magnitud market pressur current market
drug within portfolio import driver
valuat keytruda cancer close quarter
sale come keytruda impact competit
new clinic data significantli affect import drug
merck lastli ad potenti
healthcar polici reform relat drug price bear
case creat addit pressur
patent economi scale power intellectu
base buoy merck busi keep well shield
competit bedrock merck wide moat
patent protect continu keep competitor
bay compani strive introduc next
gener drug compani enorm cash
flow support power salesforc sell
current market drug also serv deterr
develop drug compani seek launch compet
opportun extern develop drug cash flow
also put compani rare posit support
approxim million need averag
bring new drug market power
merck research laboratori still hold
vast databas knowledg help compani
maintain leadership posit drug discoveri
develop also compani entrench
immuno-oncolog area strengthen
merck competit posit drug carri
strong price power area unmet medic need lastli
merck strong entrench vaccin add layer
competit protect intellectu properti cost
advantag firm large-scal product enabl
cardiovascular heaviest near-term patent loss
close four year gener like diabet
drug januvia howev believ pipelin drug
growth exist drug off-set gener
headwind overal expect improv margin
near term overal sale repres
specialty-ori drug carri strong price power
maintain uncertainti rate merck
medium overal larg base cash flow
divers inelast product portfolio rate merck
uncertainti medium view merck uncertainti
medium rather low due increas import
keytruda look well posit partli reduc
merck product divers cash flow scenario
analysi assum base-cas fair valu estim
bull case probabl bear
rel base case scenario analysi show
modest varianc henc medium uncertainti rate
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
face deterior moat trend past merck
competit advantag stabil patent protect
still shield major drug competit
compani develop enough new drug off-set
eventu patent loss pipelin side merck made
strateg shift acceler move focu
unmet medic need specialti care area
debilit lethal diseas strateg shift help
increas product fight back
follow three neg trend first post-vioxx era
food drug administr grown increasingli
risk-sensit primary-car diseas tend approv
safe drug drug highli need area
cancer second insur compani steadili
reduc coverag follow-on drug forc drug firm
push true innov reduc power
distribut network lastli govern
develop market increasingli use compar
effect program aggress push
price negoti respons challeng merck
strateg focu toward unmet medic need
increas probabl success regulatori agenc
support stronger pharmaceut price power
payer fewer altern exist treatment area
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
okeytruda look best posit immuno-
advantag import indic first-lin non-
landscap buoy
oth growth merck high margin cancer drug
help expand compani overal oper
omerck support strong dividend yield look
secur base wide diversifi portfolio drug
ooutsid immuno oncolog merck need increas
number late-stag pipelin drug
owhil major patent loss behind
compani firm face gener competit
januvia potenti earli
oadvanc oncolog happen quickli
could caus disrupt merck lead growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
merck remain solid financi foot compani
close debt/capit strong cash flow
expect next sever year
strengthen balanc sheet howev merck signal
strong willing make acquisit histor
tend make sever bolt-on acquisit year
given merck made major acquisit sinc
schering-plough deal expect make
larger acquisit next two three year beyond
acquisit expect steadi futur dividend support
pay-out ratio close rel adjust
merck near-term risk larg center market accept
new drug like pharmaceut compani merck
face regulatori risk fda product delay
nonapprov could hurt stock also grow power
manag care price-sensit
addit merck face remain legal risk
vioxx major plaintiff particip
billion settlement holdout could ring major
addit settlement also litig risk remain
patient took one-tim blockbust fosamax
osteoporosi medicin link infrequ
seriou side effect lastli grow success
keytruda increas firm depend drug
growth could becom problemat side
effect show new therapi emerg quickli treat
cancer howev overal view merck uncertainti
medium given wide divers larg inelast drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
mr kenneth frazier ceo/chairman board/
repres date owner name posit common share held report holder issuer
capit research manag compani
share
fund
share
fund
ken frazier took ceo dick clark begin
appoint chairman board late
clark near retir age view
new leader continu merck past strategi
red flag shift leadership approach frazier
part success strategi guid clark frazier
almost two decad experi merck across
major divis posit well lead
compani also deserv much credit
success handl vioxx litig held
merck gener counsel posit major
litig merck board pack current retir
ceo lead quid pro quo compens
top execut
rate compani stewardship standard merck
shown reason use capit purchas
schering-plough fair price brought sever
import pipelin product includ keytruda
allow cost-cut opportun hand
billion acquisit cubist seem like stretch
make valuat work especi announc
sooner-than-expect patent loss key drug cubicin
merck heavi fund past decad
produc mix result sever import new drug
also mani failur howev compani shift
 focu toward area specialti care away
primari care continu support improv
product success keytruda exampl
new focu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
roch bristol report compel data
set like market loss merck may
roch bristol-my squibb releas data
annual american societi clinic oncolog meet
weigh merck lead spot import non-
small-cel lung cancer market base data
increas roch fair valu estim
decreas merck fair valu estim
maintain bristol fair valu
estim see immuno-oncolog platform
firm strong support wide moat rate
roch releas strong tiragolumab phase data first-lin
nsclc combin tecentriq reduc risk
progress death patient high level
express versu tecentriq alon also
tiragolumab didnt appear add safeti concern
data need confirm phase studi data like
monotherapi benefit tecentriq
unusu low set potenti stronger rel
perform tiragolumab still believ data
strong enough support increas assum market
share roch nonsquam nsclc
larg expens merck share fall
merck develop anti-tigit drug
similar mechan action tiragolumab like
data chemotherapi still hold excel data set
high bar new therapi
bristol also report data attack merck leadership
nsclc data checkmat doesnt look
significantli chang
surviv fairli similar benefit seen
merck keytruda plu chemotherapi howev
low patient area keytruda effect
abl will take chemotherapi long term bristol
combo still look well posit gain close
overal nsclc market
merck report mix coronaviru crowd
physician-given drug stock look under-valued
merck report mix first-quart result strong
report sale also lower full-year earn
guidanc midpoint new rang dont
expect major chang fair valu estim
believ weaker outlook revers
normal
util follow better control around coronaviru
merck reduct guidanc notabl drug
compani havent lower guidanc howev
viru like disrupt merck firm gener
close two third human health busi
physician-administ product also merck one
drug compani anim health busi
total sale vulner reduc
veterinari consumpt demand
coronaviru concern despit headwind
continu view merck under-valued market
fulli appreci firm strong immuno-oncolog
posit also support wide moat
quarter strong sale cancer drug keytruda
help lift overal sale expect overal
slow sale coronaviru concern crowd
doctor-administ treatment follow growth
rebound given sever underli diseas
cancer strong benefit vaccin
expect strong rebound physician-administ drug
merck particular keytruda sale
europ acceler base recent reimburs
approv larg indic first-lin non-small-cel
lung cancer recent keytruda submiss six-week
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
dose help patient want avoid doctor
offic differenti drug four-week
dose compet drug also expect import
keytruda data adjuv earlier stage lung cancer
studi could expand market potenti
close
background adjuv lung cancer potenti
immuno-oncolog drug pleas see report immuno-
oncolog drug adjuv lung frontier
strengthen moat also complet review
potenti impact coronaviru drug biotech
industri pleas see report coronaviru caus
limit impact pharma
coronaviru affect drug firm moat
slightli lower pharma
fair valu estim almost aggreg much less
stock declin result disrupt
caus coronaviru outbreak high need drug
support continu demand suppli also
expect new treatment vaccin reduc long-
term impact viru expect chang
moat rate innov continu minor
disrupt success coronaviru treatment
pharmaceut industri also remind world
social import group key esg factor
industri shield potenti pressur
look bigger pictur around coronaviru
challeng view four key point drug biotech
industri first expect much impact drug sale
econom disrupt coronaviru caus
drug demand tend highli inelast
govern like priorit drug suppli second
drug util near term like face disrupt
especi new drug drug new indic
expect entrench drug face minor
impact third beyond capit appreci view
dividend group secur averag pay-out
ratio close give firm room adapt near-
term coronaviru pressur last expect new medicin
vaccin emerg treat coronaviru limit
background outlook coronaviru
impact pharma industri
pleas see report titl coronaviru caus limit
impact pharma moat valuat
dividend look attract market pullback
defens natur healthcar firm offer
concern around global recess due coronaviru
disrupt weigh global market
defens natur healthcar hold rel
basi dont expect signific chang
healthcar moat rate may make downward
adjust valuat healthcar account
near-term challeng expect modest chang
rel recent stock price movement base case
call strong econom rebound follow
recess modest impact
healthcar valuat given defens natur
compani howev coronaviru pandem exert
sustain impact economi significantli higher
number patient unemploy uninsur
underinsur could reduc healthcar demand
greater extent expect govern effort reduc
near-term hit keep harder-hit industri
busi effect treatment emerg
near-term effect coronaviru expect critic
therapi crowd elect procedur new
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
product non-critical-car product fewer elect
procedur weigh devic maker servic
focus covid-specif case could reduc
profit health insur brand drug firm
alreadi focus specialti drug expect less impact
industri drug administ hospit could
still feel crowd coronaviru patient also
clinic develop timelin probabl face
delay due coronaviru disrupt like slow
new product launch addit coronaviru
impact credit market could weigh heavili
indebt compani hospit firm
compani recent complet major acquisit
outlook coronaviru global
economi well potenti new treatment
coronaviru pleas see
widespread diseas drug pipelin progress
outlook chang drug price polici
initi result super tuesday democrat primari
show increas support former vice presid biden
whose nomin would reduc likelihood signific
drug price polici chang line
expect dont expect major chang fair
valu estim moat rate drug biotech
industri base result continu view
industri under-valued averag
due partli excess concern around potenti major
drug polici chang note elect result
bigger impact healthcar insur servic
relief ralli health insur servic provid
drug side movement toward moder
democrat biden like mean minor drug polici
chang reduc chanc medicar
scenario champion biden key oppon sen
berni sander would like significantli reduc
drug price negoti power one-pay
system elect support shift toward biden
believ like chang drug price polici
reform center around senat bill prescript drug
price reduct act pdpra howev still believ
propos hold less chanc pass base
mix level support parti havent
includ passag bill model howev
pass estim aggreg hit brand
drug sale medicar inflat price cap part
redesign propos bill believ drug
biotech industri could adapt headwind
minor impact cash flow partli cost cut
increas volum base lower price mandat
bill importantli bill would limit out-of-pocket
payment patient medicar would like help
appeas demand lower drug price
potenti drug polici chang key element
esg analysi drug firm pleas see recent
healthcar observ esg risk affect moat
pharma morningstar
increas growth outlook keytruda depend
plan maintain fair valu estim merck
follow slightli disappoint fourth-quart earn
solid guidanc along surpris spin-off
announc sever legaci drug platform includ
women health biosimilar continu view
compani under-valued market fulli
appreci firm strong posit immuno-oncolog
led keytruda addit dont expect spin-off
older product line impact merck wide moat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
support strong portfolio drug gener cash
flow develop next gener drug
merck decis divest older legaci drug
billion expect sale close sale
set faster sale growth focus
compani less product sale depend
keytruda grow merck plan spin-off
first half enabl slightli faster growth
remain compani spin-off give merck
billion special dividend expect
merck use share buyback small tuck-in
acquisit howev loss legaci drug
expect growth keytruda expect merck
depend keytruda grow almost total
sale current keytruda hold
excel outlook increas depend one drug
turn quarter overal sale growth
quarter led cancer drug keytruda
expect keytruda lead overal growth next sever
year support lead efficaci lung cancer like
new indic earlier use set lower sale
human papillomaviru vaccin gardasil partli due shift
inventori weigh quarter expect
vaccin return growth driven intern market
look concern around price pressur
pharmaceut believ merck
posit portfolio vaccin drug howev
spin-off legaci product increas merck
sale price concern
elev key element esg analysi
merck price posit aspect esg
includ legal issu pleas see recent healthcar
observ esg risk affect moat valuat
pharma morningstar sustainalyt offer
sustainalyt esg risk methodolog
point opportun pharma/biotech jan
sustainalyt
own
collabor broaden deepen
esg analysi incorpor environment social
govern factor valuat analysi
pharma focus
materi esg issu social realm think
firm expos esg risk morningstar
conclud valuation-affect esg risk brand
drug firm center price risk larg litig
provid comprehens evalu support
mostli wide moat rate industri
overal see under-valued name roch
biomarin lowest exposur esg-rel
strategi focu sever diseas lower price
pressur includ base case alreadi factor much
potenti headwind intern benchmark
price could test medicar part
biomarin global price strategi rare-diseas drug
well seriou natur condit limit futur
price litig risk despit high price tag
medicar exposur minim
also like sanofi
valuat esg risk johnson johnson eli lilli look
least compel us base litig risk
valuat look under-valued
detail analysi price litig issu
top pharma name
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
enact expect similar limit around
recent propos given complex distribut
differ drug label countri see poor
prospect wide use drug re-import
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued within
report highlight impact enact chang
drug payment increas discount
medicar part doughnut hole sale also review
depth drug polici propos council
econom advisor budget
coverag see januari
healthcar observ esg risk affect moat
pharma morningstar
trump propos drug reimport look limit
potenti lower drug price dec
trump administr move allow drug import
canada look challeng implement
limit scope dont expect major chang
fair valu estim drug biotechnolog
industri view administr move driven
polit motiv anoth elect cycl draw
near rather major structur shift influenc drug
price continu view price power drug
strong central pillar support moat rate
larg drug biotechnolog compani
import action propos
human servic juli propos rule
releas fda decemb dont view
plan major driver lower drug price think
implement chang would difficult
practic hard reconcil safeti provis
part feder track-and-trac system stop
counterfeit drug ensur enough drug-firm suppli low
price canada anoth concern drug firm could
limit distribut limit re-import also canada would
like support plan low drug price would
like face rise pressur support price
implement scope drug target potenti
re-import limit exclud drug biolog
inject drug drug subject fda risk evalu
mitig strategi rem drug group repres
core area focu new drug reach market
congress support drug re-import past
safe implement propos limit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
